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Abstract 
 
OBJECTIVE: To determine whether or not Orlistat ingested prior to a meal causes an increased 
appetite response. 
 
STUDY DESIGN:  A Review of three randomized controlled trials studies from 2003-2008 that 
were in the English language. 
 
DATA RESOURCES:  Randomized controlled trials comparing the effect of Orlistat on satiety 
were found using PubMed, OVID, and Cochrane databases. 
 
OUTOMES MEASURED:  Outcomes measured in the studies were: sensation of appetite, 
hunger, fullness, nausea, bloating, heartburn, belching, epigastric burning, and prospective food 
consumption.  Each study measured individual patient responses using a VAS (visual analogue 
scale).     Demarchi et al (2004) used a gastric barostat to measure gastric distention and 
accommodation to a meal. Both Demarchi (2004) and  Goedecke et al (2003) measured plasma 
CCK levels and Ellrichmann et al (2008) measured gherlin, GLP-1, and PYY in addition to 
CCK.  In addition, Ellrichmann et al (2008) used an ultrasound to determine changes in 
gallbladder size, and gastric emptying using a C sodium-Octanoate breath test. 
 
RESULTS:  Results from both the Demarchi (2004) and  Goedecke et al (2003) studies did not 
demonstrate any significant increase in appetite or inhibition of anorexogenic hormones with 
Orlistat treatment prior to a test meal. The Ellrichmann et al (2008) results demonstrated 
decreased gallbladder contractility, increased appetite and food consumption. 
 
CONCLUSIONS:  The results of whether Orlistat ingested prior to a meal causes an increased 
appetite response has not been shown in two of the three studies reviewed. Future tests should 
include varied fat concentrations in a diet and administered to the same subjects with testing 
trials in longer duration. Orlistat is still an effective dietary aid in the battle against obesity in 
today’s society. 
 
KEY WORDS:  Orlistat, appetite, satiety, diet, obesity, treatment, intervention, weight loss
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Introduction 
     Overweight and obesity is a preventable disease that is associated with significant increases in 
both morbidity and mortality. Overweight is defined as having a BMI over 25 and obesity is 
having a BMI over 30. Over 68% of adults in the US are overweight,4 and about one-third of 
U.S. adults (33.8%) are obese.1 These statistics place obesity and overweight one of the most 
common medical conditions in every field of practice. Non-Hispanic black women and 
Hispanics have the highest rates of obesity (41.9% and 30.7%)1. 
     The conditions also impose an additional cost. On average, people who are considered obese 
pay $1,429 (42 percent) more in health care costs than normal-weight individuals.1 The total cost 
due to obesity in the US is estimated to be $117 billion.5 Physician office visits related to obesity 
totaled 62.7 million in 2008.5 A majority of additional costs entailed by the patient may be due to 
the complications of obesity such as reproductive, endocrine, gastrointestinal, cardiovascular, 
pulmonary, and conditions such as dyslipidemia, metabolic syndrome, cancer, insulin resistance 
and Type 2 diabetes.2 
     The cause of overweight and obesity come from energy imbalance, and there is no single 
cause of obesity. In addition, genetic, environmental, behavioral, and socioeconomic factors can 
all lead to overweight and obesity. Body weight regulation has both a neural and endocrine 
component that effect energy intake and output. Treatment for the condition is centered on these 
two components. Behavioral and dietary lifestyle modifications with a focus on less calories, fat 
and sugar, along with exercise is the treatment of choice and has the most success long-term.5 
Other treatments include pharmacologic such as a lipase inhibitor, appetite suppressants 
(adrenergic or norepinephrine/serotonin reuptake inhibitor), and bariatric surgery. 
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     Appetite and satiety is influenced by many factors that are integrated by the brain, most 
importantly in the hypothalamus.3 Hormones, neural afferents, and metabolites may influence the 
hypothalamic center. Gut peptide hormones such as ghrelin (from stomach to influence feeding), 
glucagon-like peptide-1-(7-36)-amide (GLP-1), peptide YY (PYY), and cholecystokinin (a.ka. 
CCK, which is produced in the small intestine) all influence appetite via the vagus nerve. When 
there is adequate  digestion of dietary triglycerides by pancreatic lipase to produce FFAs (Free 
Fatty Acids) anorexigenic hormones, CCK, GLP-1, PYYare released, which in turn, will 
increase satiety. In addition, CCK levels directly influence gallbladder emptying 
     Americans spend $33 billion annually on weight-loss products and services.5 Several weight-
loss products and services are available in the US market, and diet pills are a popular choice. One 
of them is Orlistat which is a lipase inhibitor. A pharmaceutical agent Orlistat, is the only FDA 
approved drug to prevent fat absorption in the body. A proposed theory is that Orlistat 
accelerates gastric emptying, and inhibits gallbladder motility with reduced secretion of GLP-1, 
PYY and CCK. . Therefore, Orlistat may actually cause an increase in appetite and potentially 
cause weight-gain, or unchanged weight status.  This paper evaluated three randomized 
controlled studies (single blind, double blind) comparing the use of a lipase inhibitor to a placebo 
in appetite after an ingested meal. 
 
Objective  
     The objective of this selective EBM review is to determine whether or not Orlistat ingested 
prior to a meal causes an increased appetite response. 
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Methods  
     The studies included healthy non-obese men and women aged 19-32 who were pre-prandial 
and given Orlistat 120 mg prior to a meal. Included in this analysis were a double-blind 
randomized crossover design which compared a five-day regimen of Orlistat 120 mg tablet three 
times daily pre-prandial each meal against a visually matched placebo 120 mg; a randomized, 
single-blind, placebo-controlled, crossover trial which compared Orlistat 120 mg tablet against a 
visually matched placebo 120 mg ingested with a test meal; and a randomized, single-blind, 
placebo-controlled, crossover trial which compared Orlistat 120 mg tablet against a visually 
matched placebo 120 mg (2 g flour)  ingested with a high fat meal after an overnight fast. See 
Table 1 for an outline of the patient demographics and characteristics. 
     Research sources used were PubMed, OVID, and Cochrane databases.  Articles for this 
systemic review were located by key words “orlistat”, “satiety”, “appetite”, and “weight loss”.  
All articles were published in English, in peer reviewed journals, were selected based on the 
importance of outcomes and relevance to patients.  Inclusion criteria included randomized 
controlled, double blind, single blind, cross-over trials involving healthy non-obese individuals 
(BMI<30)  aged 19-32. Studies excluded were outcomes not patient oriented such as hormone 
and enzyme level responses. To successfully measure patient outcomes, the following statistical 
methods were utilized:  r2, p-values, AUC, ANOVA, and α level. 
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Table 1 – Demographics and Characteristics of included studies 
Study Type # 
Pts 
Age Inclusion Criteria Exclusion 
Criteria 
W/D Interventions 
Goedecke6 
2003 
Randomized, 
single-blind, 
placebo-
controlled, 
crossover trial 
19 Mean age 
21±1.6y 
• BMI:<30kg/m2 
• Absence of 
known 
metabolic 
conditions 
• No medications 
for chronic 
conditions 
• Obese pts. 
w/ BMI>30 
0 (2) 
Randomized 
trials 
separated by 2 
wks. where 
subjects 
ingested test 
meal w/ 
Orlistat 
(120mg) or 
placebo (2g 
flour) 
Demarchi7 
2004 
Double-blind 
randomized 
cross-over 
design 
18 Mean age 
24±1.11y18-
32 
• Healthy pts. 
with no pre-
existing 
medical 
condition 
• Currently 
on 
medication 
• Symptoms 
or history of 
gastrointesti
nal disease 
• Drug 
allergies 
• Major 
abdominal 
surgery 
0 (5) day 
regimen of 
120 mg 
Orlistat tablet 
three times 
daily pre-
prandial each 
meal and a 
visually 
matched 
placebo 
Ellrichmann8 
2008 
Randomized, 
single-blind, 
placebo-
controlled, 
crossover trial 
25 20-32 
years 
BMI in normal 
range 19.1-25.0 
kg/m2 
• History of 
GI or 
endocrine 
disorders 
0 Oral dose of 
Orlistat 120 
mg ingested 
with a test 
meal after an 
overnight fast 
 
 
Outcomes Measured  
     Each study measured individual responses using a VAS (visual analogue scale) and each 
study measured a variety of outcomes. Goedecke et al had patients mark their appetite sensation 
on a 100 mm line from “not at all full” (0mm) to “extremely full” (100 mm). Ellrichmann et al 
measured the effects of Orlistat on sensation of appetite, hunger, fullness, and prospective food 
consumption. 
     Demarchi et al had patients rate gastrointestinal sensation of fullness including bloating, 
nausea, heartburn, belching, epigastric burning, discomfort and satiety. There were two test 
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periods with the test duration of 5 days and a washout period of 3 weeks. In addition, sensitivity 
to gastric distention and accommodation to a meal was measured using a gastric barostat. 
Venous blood samples were taken before and after a meal at timed intervals to measure plasma 
CCK. Satiety was measured using a VAS with an interval of 5-43 days. During the satiety test, 
the patients scored sensations every 5 minutes. 
     Goedecke et al completed two randomized trials with a recovery period of 2 weeks between 
each trial. Satiety and hunger were measured along with blood sampling for CCK levels pre-
prandial and every hour after a test meal for 4 hours. Patients rated motivation to eat such as 
hunger, satiety, fullness and prospective consumption prior to a meal and every hour up to 4 
hours post meal using a VAS. At 4 hours post-prandial, the patients were given lunch with no 
limits on quantity based on their appetite. 
     Ellrichmann et al trial was conducted on two separate trials. Plasma concentrations of gherlin, 
GLP-1, CCK, and PYY were obtained pre-prandial and 2 hours postprandial. Ultrasound 
measurements were used to determine Gallbladder size 120 minutes post-prandial, and gastric 
emptying was measured using a C sodium-octanoate breath test. A visual analog scale was used 
at 15-minute intervals over a period of two hours after ingestion of a meal.  
      
Results 
     In the Ellrichman et al (2008) study, the administration of Orlistat led to significant inhibition 
of gallbladder contractility. In addition, the rise in postprandial plasma concentrations of GLP-1, 
PYY, and CCK was significantly lower after Orlistat administration. The mean satiety ratings 
were reduced by 15% after Orlistat treatment and fullness was lowered by 12%. Orlistat 
treatment caused a significant increase in appetite (24%) and prospective food consumption 
(31%). There was a linear relationship between gallbladder emptying and the plasma levels of 
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CCK, PYY, and GLP-1.  A decrease in gallbladder contractility decreased levels of the plasma 
anorexigenic hormones.  In addition, there was positive correlation between the ratings of satiety 
and fullness and gallbladder emptying, and hunger and food consumption were inversely related. 
There was statistical significance between satiety and incremental concentrations of CK (r2=0.41, 
P<0.0001) and GLP-1 (r2=0.14, P=0.0064). The rise in postprandial plasma concentration of 
GLP-1, PYY, and CCK was significantly lower after Orlistat administration.8 The statistical 
significance is demonstrated in Table 2. 
 
Table 2:  One-Way ANOVA statistical analysis of GLP-1, PYY, CCK and Ghrelin plasma 
concentrations placebo vs. administration of Orlistat8 
Hormone Differences Between 
Experiments 
Differences Over Time Differences due to 
Interaction of 
Experiment and Time 
GLP-1 p=0.015 p<0.0001 p=0.002 
PYY p=0.16 p<0.0001 p<0.001 
CCK p<0.0001 p<0.0001 p<0.0001 
Ghrelin p= 0.77 p<0.0001 p=0.18 
 
     In the Goedecke et al study, Orlistat was not shown to alter the ratings of hunger, satiety, 
prospective consumption or fullness while examining changes over time (Table 3). There were 
no differences in post-test meal intake between the Orlistat and placebo trials. The plasma CCK 
response showed no significant difference in response to the high-fat meal with Orlistat 
compared to placebo administration. However, the study showed variability in CCK 
administration due to variability in body fatness. BMI correlated negatively with plasma CCK 
for both the Orlistat and placebo trials (R=-0.690, P=0.001 and R=-0.649, P=0.003 respectively 
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Table 3:  Area under the curve for appetite scores in response to the high-fat test meal with 
Orlistat and placebo administration6 
 Orlistat Placebo P-value 
Hunger (mm x 4hrs) 14,866 ±5324 15,021 ±5376 0.848 
Satiety (mm x 4 hrs) 13,378 ±4626 13,208 ±5516 0.755 
Fullness (mm x 4hrs)   6,898 ±3422   7,675 ±4293 0.360 
Prospective Intake (mm x 4 hrs) 16,697 ±4259 16,631 ±4081 0.924 
 
 
     In the Demarchi et al double-blind, randomized, crossover study, sensitivity to gastric 
distension and gastric accommodation to a meal was studied using a gastric barostat. Two test 
periods of 5 days each were completed. The fasting perception and discomfort thresholds during 
fasting distentions with Orlistat did not differ significantly from the placebo. The area under the 
curve (AUC) of perception scores during fasting isobaric distentions with the placebo and the 
Orlistat pre-treatment showed no significant differences as outlined in Table 4. 
 
Table 4:  Area under the curve of perception scores in response during fasting isobaric 
gastric distentions with placebo and Orlistat pre-treatment7 
 Placebo Orlistat 
Fullness 70±11 80±9 
Bloating 81±12 78±10 
Satiety 76±16 75±10 
Discomfort 78±10 77±11 
Belching 44±12 28±7 
Nausea 35±13 23±8 
Epigastric burning 66±11 64±10 
Heartburn 42±13 31±10 
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During postprandial distentions the postprandial pressure-volume curves did not differ between 
both treatment groups. In addition, treatment with Orlistat, first perception and discomfort 
thresholds were not significantly altered as outlined in Table 5. 
 
Table 5:  Area under the curve (AUC) of perception scores during postprandial isobaric 
gastric distentions, with placebo and Orlistat pre-treatment (no significant differences)7 
 Placebo Orlistat 
Fullness 94±13 70±11 
Bloating 95±13 70±11 
Satiety 98±14 70±13 
Discomfort 97±13 70±11 
Belching 47±18 70±10 
Nausea 54±16 70±13 
Epigastric burning 63±13 70±12 
Heartburn 37±13 70±12 
 
     Serum CCK analysis after Orlistat pre-treatment demonstrated lower levels when compared to 
the placebo. CCK levels, P=0.09, and preprandial AUC, P=0.06. In post-prandial CCK levels 
(P<0.01) and the postprandial AUC (P=.0.3) were significantly lower after orlistat pre-treatment.  
A satiety test both after the placebo and Orlistat treatments showed a high correlation between 
satiety scores and the amount of calories ingested (R>0.95, P<0.0001). Pre-treatment with 
Orlistat did not significantly alter the amount of calories ingested until maximum satiety as 
compared to placebo shown in Table 6. 
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Table 6:  Area under the curve (AUC) of perception scores during the satiety drink test, 
with placebo and orlistat pre-treatment7 
 Placebo Orlistat 
Fullness 207±15 190±13 
Bloating 160±21 149±17 
Satiety 148±11 135±10 
Discomfort 119±24 140±19 
Belching 76±14 87±17 
Nausea 61±11 55±16 
Epigastric burning 40±10 59±15 
Heartburn 27±8 34±10 
     
Discussion 
     The articles used in this EBM review demonstrate that the control of gastric sensitivity and 
gastric accommodation to a meal is incompletely understood7.  Lipid digestion and subsequent 
release of CCK and activation of CCK B receptors are key factors in gastric emptying and 
sensitivity. 
    There were contradictory findings between the studies that examined to effects of Orlistat on 
satiety.  Both the Demarchi et al (2004) and Goedecke et al (2003) did not demonstrate findings 
that an oral lipase inhibitor, Orlistat, would significantly reduce plasma CCK release to influence 
gastric sensitivity with sensation of hunger or satiety in response to a meal. Although lowered 
CCK levels were observed with Orlistat pre-treatment prior to a meal in these studies, the 
medication had no effect on calories consumed, gastric distention, and failed to elicit any 
symptoms of increased appetite. 
     On the other hand, Ellrichmann (2008) did show increased appetite with the administration of 
Orlistat with the relationship of inhibition of CCK, GLP-1, and PYY release. The tests 
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demonstrated Orlistat accelerates gastric emptying.  Ghrelin, another anorexigenic hormone, was 
unaffected.  The experimental testing took place for up to 120 minutes only versus the other 
studies consisted of a longer length time period for testing. 
           
Conclusion 
     Two of the three studies reviewed demonstrate overall, that the use of Orlistat does not cause 
an increase in appetite in healthy patients. One study showed an increase in appetite but the study 
duration was a shorter time period limited to just 2 hours which places the validity of the study in 
question. The response to symptoms related to satiety was subjective using the VAS and were 
subject to potential varied responses based on the patient’s tolerance and interpretation. In 
addition, varied results between the studies may also be directly correlated to the diet the patients 
were given, where fat content plays an important role in measuring the body’s response. Future 
studies could include varied amounts of fat content in test meals and measure responses in both 
anorexigenic hormones and subjective ratings by the patients. 
     If continued to use as directed, Orlistat can be an effective weight loss regimen adjunct to 
healthy lifestyle changes.  
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